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Background: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barrett’s esophagus (BE)
increases the risk for EAC. Studies have reported inconsistent findings on the association between use of cyclooxygenase (COX)
inhibitors and the risk of neoplastic progression in BE patients. Therefore, we performed a meta-analysis to investigate this
association.
Methods: A meta-analysis was undertaken among a total of 9 observational studies using fixed- and random-effects models,
comprising 5446 participants; 605 had EAC or high-grade dysplasia (HGD).
Results: Overall, COX inhibitors use was associated with a reduced risk of EAC/HGD among BE patients (relative risk (RR)¼ 0.64,
95% confidence interval (CI)¼ 0.53–0.77). Aspirin use also reduced the risk of EAC/HGD (RR¼ 0.63, 95% CI¼ 0.43–0.94), as well as
non-aspirin COX inhibitors (RR¼ 0.50, 95% CI¼ 0.32–0.78). The chemopreventive effect seemed to be independent of duration
response.
Conclusions: Cyclooxygenase inhibitors use is associated with a reduced risk of developing EAC in patients with BE. Both
low-dose aspirin and non-aspirin COX inhibitors are associated with a reduced risk of neoplasia. More well-designed randomised
controlled trials are needed to increase our understanding of the chemopreventive effect of COX inhibitors.
The incidence of esophageal adenocarcinoma (EAC) has increased
dramatically over the past decades (Bollschweiler et al, 2001;
Vizcaino et al, 2002). With high mortality, EAC has become the
most universal histological type of esophageal cancer in western
countries (Polednak, 2003; Vaughan et al, 2005). Barrett’s
esophagus (BE), defined as a premalignant condition in which
any extent of metaplastic columnar epithelium replaces the normal
stratified squamous epithelium of the distal esophagus, has
generally been regarded as the only established precursor lesion
for EAC (Spechler et al, 2011). BE is a relatively common condition
with an estimated prevalence of about 1–2% in the general
population (Ronkainen et al, 2005), and B10–15% in patients
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undergoing endoscopy for gastroesophageal reflux disease (GERD)
(Sharma and Sidorenko, 2005). In patients with non-dysplastic BE,
the annual incidence rate of developing EAC is estimated to be
around 0.33% (Desai et al, 2012). However, the time course
and risk factors for the progression of BE to EAC remain largely
unknown.
The increasing incidence of EAC and its poor prognosis have
led to a search for methods to prevent the neoplastic progression
of BE. Many studies, including three meta-analyses, have
supported the potential of chemoprevention with cyclooxygenase
(COX) inhibitors, including aspirin, non-selective non-steroidal
anti-inflammatory drugs (nsNSAIDs), and selective COX-2
inhibitors, for esophageal cancer (Corley et al, 2003; Abnet
et al, 2009; Sun and Yu, 2011). Corley et al demonstrated a
protective association between COX inhibitors use and
esophageal cancer (of both histological types) and provided
evidence for a dose effect. Abnet et al found that COX inhibitors
use was inversely associated with EAC in their meta-analysis.
Moreover, Sun et al reported that COX inhibitors reduced the risk
for esophageal squamous cell carcinoma. An important limitation
of these studies is the absence of information on BE states in the
patients. Thus COX inhibitors could exert their antitumour effect
either by reducing the risk of BE patients progressing into EAC,
or by reducing the risk of BE. Since BE is the only known
precancerous lesion for EAC, any cancer reducing effect for COX
inhibitors should be best shown among BE patients. And
chemoprevention for EAC would not be advocated on a
population level. However, it could reasonably be considered in
high-risk groups, such as patients with BE.
Inhibition of the COX-2 enzyme is hypothesised to be one of the
mechanisms by which COX inhibitors might exert their anti-
tumour effects. Increased expression of COX-2 was observed in the
early development of many tumours including EAC and was also
found to be associated with malignant progression of BE along the
metaplasia-dysplasia-adenocarcinoma sequence (Molina et al,
1999; Fosslien, 2000; Shirvani et al, 2000; Kandil et al, 2001;
Morris et al, 2001; Spechler et al, 2011). Substantial experimental
data also suggest that COX inhibitors might be effective
chemopreventive agents for patients with BE. For example, COX
inhibitors, both selective and non-selective, have been found to
decrease the progression of EAC in animal models of GERD or BE
(Buttar et al, 2002; Oyama et al, 2005; Kim et al, 2007). Rofecoxib
was reported to reduce cell proliferation in biopsy specimens of
Barrett’s epithelium taken from patients (Kaur et al, 2002).
Thus, we suggest that COX inhibitors might have an important
role in preventing BE from developing into dysplasia or
adenocarcinoma.
To date, only a few epidemiological studies with inconsistent
results have been carried out in patients with BE. A randomised-
controlled trial (RCT) published in 2007 by Heath et al (2007)
demonstrated that secondary chemoprevention with celecoxib
did not reduce the risk of developing EAC in patients
with BE. Although some meta-analyses on the chemopreventive
effect of COX inhibitors in esophageal cancer with limitations
have been performed (Corley et al, 2003; Abnet et al, 2009;
Sun and Yu, 2011), no meta-analyses assessed the association
between COX inhibitors use and progression to EAC in patients
with BE. So, the protective effect of COX inhibitors on the
neoplastic development in patients with BE has remained
uncertain.
We therefore performed a meta-analysis of existing observational
studies to investigate the association between COX inhibitors
ingestion and the risk of neoplastic progression in patients with
BE, following the MOOSE guidelines (Stroup et al, 2000). We aim to
give support to a more definitive answer on whether preventive use
of COX inhibitors can reduce the risk of neoplastic progression in
patients with BE.
MATERIALS AND METHODS
Search strategy. We conducted a computer-assisted systematic
search of MEDLINE, EMBASE, and Web of Science databases
from their commencement to July 2013. We used similar search
terms for MEDLINE and EMBASE (see Appendix A). Web of
Science was searched mainly for abstracts of additional gastro-
intestinal/oncology society meetings. The language of publications
was not restricted. We also reviewed the bibliographies of relevant
articles to identify additional studies that might have been missed
by the database searches.
Study selection. Two of the authors (ZS and DXW) indepen-
dently screened titles and abstracts of the papers to identify studies
that might meet the inclusion criteria and discard those that clearly
did not. Full text of studies selected for further review was retrieved
and evaluated. Studies were included if they met the following
criteria: (1) evaluated exposure to any type of COX inhibitors;
(2) the primary outcome was clearly defined as EAC or high-grade
dysplasia (HGD); (3) patients included should be definitely
diagnosed as having BE in the past or at present; (4) provided
odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) with
confidence intervals (CIs), or original data necessary to calculate
the RR.
Data extraction. All data were extracted independently and
crosschecked by three of the authors (ZS, ZXQ, and HSL)
according to the inclusion criteria. Discrepancies were discussed
and resolved by consensus. The following data were collected from
each study: the first author, publication year, the country in which
the study was performed, study design, medication type, informa-
tion source for exposure measurement (for example, questionnaire
or pharmacy database), number of participants, OR/RR/HR with
corresponding 95% CI for each category, and confounders
included in each adjusted estimate (Tables 1 and 2). Also, the
inclusion criteria and potential types of bias of each study were
provided in Supplementary Table 1. We tried to extract the risk
estimates (OR/RR/HR) from the Results section with and without
adjustment for multiple confounders. However, in some studies the
authors did not provide the unadjusted estimates but the primary
data (number of cases and controls) necessary to calculate them.
For these studies, the unadjusted RRs were calculated using the
Pearson Chi-Square test with SPSS Statistics 17 (IBM Corporation,
Armonk, NY, USA).
Statistical analysis. Stata Statistical Software was used for all the
analyses (version 12.0; Stata Corporation, College Station, TX,
USA). The measure of estimated effect of interest was the RR with
95% CI. Because the risk of EAC in patients with BE is relatively
low, the RR mathematically approximates the OR in case–control
studies and the HR in cohort studies. We therefore reported
all results as the RR for simplicity, and summary RR estimates
were calculated using RR, OR, or HR reported in each study
(Greenland, 1987).
The Q and I2 statistics were used to test statistical heterogeneity
among studies (Higgins and Thompson, 2002). If the results were
homogeneous, then the fixed-effects model with Mantel–Haenszel
method should be used. Otherwise, the random-effects model with
DerSimonian and Laird method should be used (DerSimonian and
Laird, 1986; Greenland, 1994; Poole and Greenland, 1999). In this
meta-analysis, we calculated summary RR estimates using both the
fixed- and the random-effects model, and compared them to
evaluate for potential heterogeneity.
Stratified analyses were conducted for several factors including
study design, medication type (aspirin and non-aspirin COX
inhibitors) and duration of COX inhibitors use to examine
potential interactions.
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Qualitative assessment. So far, no scale has been universally
adopted for measuring quality of observational studies. Two of the
authors (ZS and ZXQ) assessed study quality independently using
the 9-star Newcastle-Ottawa Scale (NOS) (Wells et al, 2013) (see
Appendix B).
Assessment of heterogeneity. For the Q statistic, heterogeneity
was considered as statistically significant if Pp0.1 (rather
than Po0.05). I2 is the proportion of total variation contributed
by between-study variation (Higgins and Thompson, 2002),
and values of 25%, 50%, and 75% have been regarded as
Table 1. Study characteristics
Author/country/year of
publication
No. of EAC/HGD
cases/No. of
participants
Definition
of exposure
to
medications Design Exposure
Age at
baseline,
years,
mean or
range
Exposure
sourcea
Confounders
included in
adjusted
estimates
Tsibouris/UK/2004 114/496 X 2 years Case–control/Retrospective COX
inhibitors
73 (EAC)/
68.4 (BE)
Database a, b, c, d, e, f, i
E Bani-Hani/UK/2005 44/597 — Case–control/Retrospective COX
inhibitors
63.4 Database a, b, c, d, e, I, m
Vaughan/USA/2005b 37/350 At least once a
weekX6
months
Cohort/Prospective COX
inhibitors
430 Questionnaire a, b, d, g, l
Gatenby/UK/2009 20 (EAC)/30
(HGD/EAC)/736
— Cohort/Retrospective Aspirin 64.5 Database a, b, h
Nguyen/USA/2009 33 (HGD/EAC)/344 X 1
prescription
Cohort/Retrospective COX
inhibitors
60.7 Database a, b, e
Gaddam/USA/2010 185 (HGD/EAC)/1496 — Cohort/Prospective COX
inhibitors
62.8 — a, d, e, g
Nguyen/USA/2010 116/812 X 1
prescription
Nested case–control/Retrospective COX
inhibitors
65.0 Database j, k
Kastelein/The Netherlands/2011 38 (HGD/EAC)/570 nsNSAIDs
4 325mg per
day, aspirin
o 100mg per
day
Cohort/Prospective COX
inhibitors
60.4 Database a, b, e, h, k
Kantor/USA/2012 45/395 — Cohort/Prospective COX
inhibitors
430 Questionnaire a, b, d, k
Abbreviations: BE¼Barrett’s esophagus; BMI¼body mass index; COX¼ cyclooxygenase; EAC¼ esophageal adenocarcinoma; HGD¼high-grade dysplasia; PPI¼proton pump inhibitor.
a, age; b, sex; c, alcohol abuse; d, smoking history; e, BE length; f, duration of reflux; g, BMI; h, baseline histology; i, hiatus hernia; j, race; k, use of other medications, e.g., PPI and statins;
l, education level; m, esophagitis, benign esophageal stricture, ulcers or H. pylori infection.
aSource of exposure data.
bWe did not obtain this study by Vaughan in the overall meta-analysis for COX inhibitors use, but we extracted data from this study for subgroup meta-analysis considering medication type
(aspirin vs non-aspirin COX inhibitors) and duration response (shorter duration vs longer duration).
Table 2. Estimates of EAC/HGD (RR/OR/HR) in patients with BE for any COX inhibitors use in each study
Author/Year
COX inhibitors use
(case/control)a
RR/OR/HR (95% CI),
any intake, adjusted
RR/OR/HR (95% CI),
any intake, unadjusted
Tsibouris/2004 30 (26%)/147 (38%) 0.57 (0.36–0.91) 0.64 (0.44–0.94)
E Bani-Hani/2005 25 (57%)/304 (55%) 1.41 (0.68–2.93) 1.07 (0.60–1.90)
Gatenby/2009 5 (6%)/81 (11%) 0.90 (0.34–2.37)b 1.51 (0.59–3.85)
Nguyen/2009 12 (36%)/157 (50%) 0.56 (0.27–1.18) 0.51 (0.25–1.04)
Gaddam/2010 — 0.65 (0.42–0.87) —
Nguyen/2010 57 (49%)/411 (59%) 0.60 (0.40–0.92)c 0.66 (0.44–0.99)
Kastelein/2011 15 (40%)/303 (57%) 0.47 (0.24–0.93)c 0.51 (0.27–0.99)
Kantor/2012 18 (32%)/151 (43%) 0.62 (0.34–1.10)c 0.68 (0.38–1.23)
Abbreviations: BE¼Barrett’s esophagus; CI¼ confidence interval; COX¼ cyclooxygenase; EAC¼ esophageal adenocarcinoma; HGD¼ high-grade dysplasia; HR¼ hazard ratio; OR¼odds
ratio; PPI¼proton pump inhibitor; RR¼ relative risk.
aWe extracted the number of patients (case/control) with dispensed COX inhibitors prescriptions, and the actual rate of COX inhibitors use (case/control) from each individual study.
bIn the study of Gatenby et al, the adjusted HR estimating the relationship between the risk of EAC/HGD and aspirin use was 0.90 (0.34–2.37), and the adjusted HR using only EAC as the
outcome was 1.09 (0.36–3.34).
cThese estimates of the three studies were adjusted for use of other medications (PPIs and statins).
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representing low, moderate, and high heterogeneity, respectively
(Higgins et al, 2003).
We carried out several methods to avoid potential heterogeneity
as much as possible and obtain confident results. First, baseline
differences between groups and the impossibility to guarantee
randomisation could influence the results of observational studies.
So, we used each author’s reported (or calculated) RR/OR/HR with
and without adjustment for variable confounders to calculate
summary estimated RRs. Second, we performed a sensitivity
analysis by separately omitting one study at a time to assess
whether the pooled estimate has changed statistically significantly
compared with the results containing all the studies. Third, a
subgroup analysis was carried out by stratifying analyses with
several factors including study design (cohort vs case–control,
retrospective vs prospective), medication type (aspirin vs non-
aspirin COX inhibitors), and duration of COX inhibitors use
(shorter duration vs longer duration) (Kleinbaum et al, 1982;
Chalmers et al, 1983; Gerbarg and Horwitz, 1988; Schulz et al,
1994, 1995; Jadad et al, 1996; Imperiale and Birgisson, 1997).
Publication bias. Qualitative and quantitative methods were used
to assess the publication bias. We visually inspected the funnel plot,
and used Begg’s test to calculate a correlation coefficient between
the log RRs and their standard errors (Begg and Mazumdar, 1994).
Publication bias was considered to be present if Pp0.1 (Kendall
and Gibbons, 1990).
RESULTS
Study characteristics. A total of 145 potential studies were
identified with the MEDLINE search. In addition, the EMBASE
search yielded 579 and the Web of Science search 316 potentially
relevant articles. After reviewing the titles, abstracts, and some of
the full text of the studies, we selected 11 publications that met the
initial inclusion criteria (Tsibouris et al, 2004; Bani-Hani et al,
2005; Vaughan et al, 2005; de Jonge et al, 2006; Gatenby et al, 2009;
Nguyen et al, 2009, 2010; Gaddam et al, 2010; Kastelein et al, 2011;
Beales et al, 2012; Kantor et al, 2012). The studies excluded were
reduplicative, review articles, animal experiments, or those which
did not report on the subject of interest. Then all the 11 papers
were carefully read, and 2 of them were further excluded. In the
two case–control studies, the authors compared patients with BE to
patients with EAC who did not have a clear diagnosis of BE, which
could lead to loss of validity of the results (de Jonge et al, 2006;
Beales et al, 2012). We did not obtain any additional relevant study
through manual review of the bibliographies (Figure 1).
We analysed data from the remaining nine articles, among
which one was an abstract (Gaddam et al, 2010). We included 2
case–control studies, 6 cohort studies, and 1 case–control study
nested in a well-defined cohort, comprising 5446 participants, of
whom 605 were diagnosed with EAC or HGD. Because of their
characteristics, the nested case–control study was included in the
cohort study group. Among them two articles were published by
the same authors with the same population (the Seattle Barrett’s
esophagus project) (Vaughan et al, 2005; Kantor et al, 2012). We
chose the more recent one published in 2012 instead of the other in
2005 when performing the meta-analysis for overall COX
inhibitors use. Nevertheless, the study in 2005 provided risk
estimate for medication type (aspirin and non-aspirin COX
inhibitors) and duration response, while the more recent one did
not. Consequently, eight studies were included in the overall meta-
analysis for COX inhibitors use. Data from the article published in
2005 were only used for the subgroup analysis considering
medication type and duration response (Vaughan et al, 2005).
All the meta-analysis results were shown in Table 4.
Quality of the included studies. The studies were judged to be 6,
7, 8, or 9 points on the 9-star Newcastle-Ottawa Scale. Seven
studies were considered to be of high quality (47 points). The
details of the quality assessment for each study are shown in
Supplementary Table 2.
Neoplastic progression (all types of COX inhibitors). Altogether
a smaller proportion of cases were prescribed COX inhibitors
compared with controls (38.6% vs 39.7%). Patients with any
exposure to any type of COX inhibitors had a significant risk
reduction in developing EAC/HGD (adjusted RR¼ 0.64, 95%
CI¼ 0.53–0.77, Phomogeneity¼ 0.512) in an overall analysis using
estimates adjusted for potential confounders in each study
(Figure 2A). The unadjusted RR was also calculated (unadjusted
RR¼ 0.70, 95% CI¼ 0.56–0.86, Phomogeneity¼ 0.357).
Then, we omitted one study at a time to see whether the
magnitude, statistical significance, or heterogeneity had substan-
tially changed. However, no study markedly influenced the result
of summary estimates.
Potentially relevant articles identified through
MEDLINE (n=145), EMBASE (n=579), and the
Web of Science (n=316) search updated to July
2013 (n=1040)
1029 articles excluded based on titles,
abstracts and some of the full texts.
Studies excluded were reduplicative,
review articles, animal experiments, or
they didn’t report on the subject of interest.
Full-text articles obtained for detailed
examination (n=11)
Studies included in the meta-analysis (n=9)
Studies excluded after full text review
(n=2)
-The authors were not able to make sure
all the esophageal cancers had a history
of BE
Figure 1. Flow diagram of study identification and selection.
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Five of the included studies used only EAC as the outcome
(see Tables 1 and 2). So, we performed a subgroup meta-analysis
among these studies and showed a significant risk reduction in
developing EAC (adjusted RR¼ 0.70, 95% CI¼ 0.52–0.95,
Phomogeneity¼ 0.238) (Figure 2B).
Study design. The adjusted estimates for cohort studies (adjusted
RR¼ 0.61, 95% CI¼ 0.49–0.76, Phomogeneity¼ 0.929) were some-
what different from the adjusted estimates for case–control studies
(adjusted RR¼ 0.86, 95% CI¼ 0.35–2.07, Phomogeneity¼ 0.04)
which was not statistically significant. (Figure 3).
Among the six cohort studies, three of them were retrospective
and the other three were prospective. So, we performed the
sensitivity analysis to investigate the difference between
retrospective cohort studies (adjusted RR¼ 0.62, 95%
CI¼ 0.44–0.87, Phomogeneity¼ 0.718) and prospective cohort studies
(adjusted RR¼ 0.61, 95% CI¼ 0.46–0.81, Phomogeneity¼ 0.709)
(see Supplementary Figure 1).
Duration response. To search for a duration response, we
performed a subgroup analysis among those studies providing
risk estimates for duration effect (Table 3).
Because the definition of longer duration in each study varied
substantially (2 months, 1 year, 2 years, 3 years, and 5 years), we
defined 1 year, 2 years, and 3 years as longer duration, and
performed subgroup meta-analysis separately (see Supplementary
Figure 2). Cyclooxygenase inhibitors use for 41 year was
associated with a significantly lower risk of neoplastic progression
Tsibouris 2004
Study ID RR (95% CI) % Weight
27.52
14.29
6.91
31.30
19.98
100.000.70 (0.52, 0.95)
0.62 (0.34, 1.10)
0.60 (0.40, 0.92)
1.09 (0.36, 3.34)
1.41 (0.68, 2.93)
0.57 (0.36, 0.91)
E Bani-Hani 2005
Gatenby 2009
Nguyen 2010
Kantor 2012
Overall (I-squared=27.5%, P=0.238)
0.5 1 1.5
Note: Weights are from random-effects analysis
Study ID
A
B
Tsibouris 2004
E Bani-Hani 2005
Gatenby 2009
Nguyen 2009
Gaddam 2010
Nguyen 2010
Kastelein 2011
Kantor 2012
Overall (I-squared=0.0%, P=0.512)
Note: Weights are from random-effects analysis
16.72
6.74
3.81
6.61
27.12
20.73
10.43
100.000.64 (0.53, 0.77)
0.62 (0.34, 1.10)
0.47 (0.24, 0.93)
0.60 (0.40, 0.92)
0.65 (0.42, 0.87)
7.84
0.90 (0.34, 2.37)
0.56 (0.27, 1.18)
1.41 (0.68, 2.93)
0.57 (0.36, 0.91)
0.5 1 1.5
RR (95% CI) % Weight
Figure 2. (A) Forest plot assessing overall COX inhibitors use and the risk of EAC/HGD in patients with BE. (B). Forest plot assessing overall COX
inhibitors use and the risk of EAC only in patients with BE.
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(adjusted RR¼ 0.54, 95% CI¼ 0.36–0.79, Phomogeneity¼ 0.999), as
compared with use for o1 year (adjusted RR¼ 0.67, 95%
CI¼ 0.46–0.97, Phomogeneity¼ 0.674). And longer duration of
COX inhibitors (42 years) was also associated with greater
risk reduction (adjusted RR¼ 0.53, 95% CI¼ 0.33–0.87,
Phomogeneity¼ 0.992) than shorter duration (o2 years) (adjusted
RR¼ 0.67, 95% CI¼ 0.46–0.97, Phomogeneity¼ 0.674). Moreover,
use for 43 years was associated with a lower risk of EAC/HGD
(adjusted RR¼ 0.54, 95% CI¼ 0.30–0.99, Phomogeneity¼ 0.952) as
compared with use for o3 years (adjusted RR¼ 0.64, 95%
CI¼ 0.46–0.90, Phomogeneity¼ 0.751). However, none of the differ-
ences between the three groups were statistically significant
(Table 4).
Medication type. Although the study by Vaughan et al (2005) was
excluded from the overall analysis for COX inhibitors use,
we included it in the subgroup analysis for medication type. We
extracted the risk estimates for aspirin and non-aspirin COX
inhibitors use from relevant studies.
Altogether four studies provided aspirin estimates adjusted for
potential confounders (Supplementary Table 3) (Tsibouris et al,
2004; Vaughan et al, 2005; Gatenby et al, 2009; Kastelein et al,
2011). Any exposure to aspirin was associated with a reduced risk
of neoplastic progression (adjusted RR¼ 0.63, 95% CI¼ 0.43–0.94,
Phomogeneity¼ 0.642). (Figure 4).
Only three studies offered the adjusted estimate for non-aspirin
COX inhibitors (Tsibouris et al, 2004; Vaughan et al, 2005;
Kastelein et al, 2011). Patients with any exposure to any type of
non-aspirin COX inhibitors also had a significant reduction in
risk of EAC/HGD (adjusted RR¼ 0.50, 95% CI¼ 0.32–0.78,
Phomogeneity¼ 0.492) (Figure 4).
Concomitant use of other medications. To explore the inter-
active effect of concomitant use of other putative chemopreventive
medications as proton pump inhibitors (PPIs) and statins, we
limited analysis to studies that adjusted for use of these additional
medications (Nguyen et al, 2010; Kastelein et al, 2011; Kantor et al,
2012), and compared results with those that did not adjust
(Tsibouris et al, 2004; Bani-Hani et al, 2005; Gatenby et al, 2009;
Nguyen et al, 2009; Gaddam et al, 2010). The results showed a 42%
reduction (adjusted RR¼ 0.58, 95% CI¼ 0.43–0.78,
Phomogeneity¼ 0.801) for those adjusting for PPIs/statins, which
was higher than those that did not adjust (RR¼ 0.70, 95%
CI¼ 0.53–0.93, Phomogeneity¼ 0.285), although this difference was
not statistically significant (Psignificance¼ 0.38).
Over-the-counter medication use. Cyclooxygenase inhibitors are
widely available over the counter and many studies have shown
that the majority of use of these drugs is not prescribed. So, we
wonder whether over-the-counter medication use will influence the
overall results. In some of the included studies, information on
medication use was collected prospectively, and patients also filled
out a questionnaire on their use of over-the-counter medication.
Besides, all information on medication use was crosschecked using
pharmacy records (Kastelein et al, 2011; Kantor et al, 2012).
In some other studies, the information on medication use was
Study ID RR (95% CI) % Weight
16.72
6.74
23.46
3.81
6.61
27.12
20.73
7.84
10.43
76.54
100.000.64 (0.53, 0.77)
0.61 (0.49, 0.76)
0.62 (0.34, 1.10)
0.47 (0.24, 0.93)
0.60 (0.40, 0.92)
0.65 (0.42, 0.87)
0.56 (0.27, 1.18)
0.90 (0.34, 2.37)
0.86 (0.35, 2.07)
1.41 (0.68, 2.93)
0.57 (0.36, 0.91)
Case–control
Tsibouris 2004
E Bani–Hani 2005
Cohort
Gatenby 2009
Nguyen 2009
Nguyen 2010
Kastelein 2011
Kantor 2012
Subtotal (I-squared=0.0%, P=0.929)
Subtotal (I-squared=76.3%, P=0.040)
Overall (I-squared=0.0%, P=0.512)
Note: Weights are from random-effects analysis
0.5 1 1.5
•
•
Gaddam 2010
Figure 3. Forest plot of COX inhibitors intake and EAC/HGD risk in patients with BE considering study design (case–control vs cohort).
Table 3. Estimates of EAC/HGD (RR/OR/HR) in patients with BE for duration response and the numbers for cases/controls
Author/Year
Case/Control (shorter
duration)
RR/OR/HR (95% CI), shorter
duration, adjusted
Case/Control (longer
duration)
RR/OR/HR (95% CI), longer
duration, adjusted
Tsibouris/2004 — — 14/88 0.51 (0.22–1.19) (daily use42 years)
Vaughan/2005 — 0.37 (0.15–0.91) (o5 years) — 0.55 (0.25–1.21) (45 years)
Nguyen/2009 6/80 0.49 (0.20–1.22) (o36 months) 6/59 0.53 (0.21–1.32) (436 months)
Nguyen/2010 43/295 0.70 (0.46–1.07) (o12 months) 14/116 0.55 (0.29–1.06) (412 months)
Kastelein/2011 10/155 0.58 (0.27–1.25) (o2 months) 5/148 0.32 (0.12–0.86) (42 months)
Abbreviations: BE¼Barrett’s esophagus; CI¼ confidence interval; COX¼ cyclooxygenase; EAC¼ esophageal adenocarcinoma; HGD¼ high-grade dysplasia; HR¼ hazard ratio; OR¼odds
ratio; RR¼ relative risk.
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collected retrospectively through questionnaires, including over-
the-counter medication use (Tsibouris et al, 2004; Bani-Hani et al,
2005). Nguyen et al (2010) thought that patients with higher
socio-economic status might be less likely to receive COX
inhibitors prescription at the Veterans Affairs pharmacy.
Consequently, their multivariate analysis adjusted for the patients’
Table 4. Meta-analysis results
Type of study
No. of studies
(patients)
RR (95% CI) random
effects
RR (95% CI) fixed
effects Pheterogeneity
I2heterogeneity
(%)
Psignificance
between
groups
All studies (adjusted) 8/5446 0.64 (0.53–0.77) 0.64 (0.53–0.77) 0.51 0
All studies (EAC only) 5/3036 0.70 (0.52–0.95) 0.70 (0.52–0.95) 0.24 28
All studies (unadjusted) 7/3950 0.70 (0.56–0.86) 0.69 (0.57–0.85) 0.36 7
Study design
Cohort studies 6/4353 0.61 (0.49–0.76) 0.61 (0.49–0.76) 0.93 0 0.41
Case–control studies 2/1093 0.86 (0.35–2.07) 0.74 (0.50–1.09) 0.04 76
Study design in cohort studies
Retrospective 3/1892 0.62 (0.44–0.87) 0.62 (0.44–0.87) 0.72 0 0.92
Prospective 3/2461 0.61 (0.46–0.81) 0.61 (0.46–0.81) 0.71 0
Medication type
Aspirin 4/2152 0.63 (0.43–0.94) 0.63 (0.43–0.94) 0.64 0 0.44
Non-aspirin COX inhibitors 3/1416 0.50 (0.32–0.78) 0.50 (0.32–0.78) 0.49 0
Duration response
Longer duration (41 year) 4/2002 0.54 (0.36–0.79) 0.54 (0.36–0.79) 1.00 0 0.42
Shorter duration (o1 year) 2/1382 0.67 (0.46–0.97) 0.67 (0.46–0.97) 0.67 0
Longer duration (42 years) 3/1190 0.53 (0.33–0.87) 0.53 (0.33–0.87) 0.99 0 0.46
Shorter duration (o2 years) 2/1382 0.67 (0.46–0.97) 0.67 (0.46–0.97) 0.67 0
Longer duration (43 years) 2/694 0.54 (0.30–0.99) 0.54 (0.30–0.99) 0.95 0 0.63
Shorter duration (o3 years) 3/1726 0.64 (0.46–0.90) 0.64 (0.46–0.90) 0.75 0
Abbreviations: CI¼ confidence interval; COX¼ cyclooxygenase; EAC¼ esophageal adenocarcinoma; RR¼ relative risk. P-values and I2 for heterogeneity were calculated using the DerSimonian
and Laird Q test. Differences between groups were considered to be statistically significant if Psignificanceo0.05.
Study ID
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0.66 (0.37, 1.17)
0.37 (0.14, 1.00)
0.90 (0.34, 2.37)
0.66 (0.27, 1.65)
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0.61 (0.32, 1.14)
0.24 (0.06, 1.05)
0.47 (0.24, 0.93)
0.50 (0.32, 0.78)
0.57 (0.42, 0.76) 100.00
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Figure 4. Forest plot of the risk of EAC/HGD associated with COX inhibitors use, organised separately by medication type (aspirin vs non-aspirin
COX inhibitors).
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social-economic status. Nevertheless, the other included studies
failed to address this problem. So, we performed a meta-analysis
among the five studies including over-the counter medication
use, and still found a significant risk reduction for COX inhibitors
(RR¼ 0.64, 95% CI¼ 0.48–0.86, Phomogeneity¼ 0.229), indicating that
over-the-counter medication use might not affect the overall results.
Publication bias. As the number of the studies included in the
analysis was small, visual inspection of funnel plots did not
demonstrate convincing patterns. Using Begg’s test to calculate a
correlation coefficient between log RRs and their standard errors,
we found there was no evidence of publication bias for overall
summary estimates of COX inhibitors use (P¼ 0.902). Considering
medication type, there was no obvious evidence of publication bias
for aspirin or non-aspirin COX inhibitors use (P¼ 0.734 for
aspirin, P¼ 0.296 for non-aspirin COX inhibitors).
DISCUSSION
In this meta-analysis, which pooled several large observational
studies, a significant negative association was found between COX
inhibitors use and the risk of neoplastic progression in patients
with BE with an overall risk reduction of 36%. A significant risk
reduction of 30% was also found for EAC development.
We observed an obvious risk reduction in cohort studies (39%
reduction), while no significant risk reduction was observed in
case–control studies, possibly due to recall bias and registration
bias. And the number of case–control studies involved was too
small to yield a convincing result. We also carried out a sensitivity
analysis among the cohort studies comparing the risk estimates
between retrospective (38% reduction) and prospective cohort
studies (39% reduction), indicating that study design in terms of
cohort studies did not affect the final results.
We also tried to explore whether there was a duration–response
effect for COX inhibitors use. The classification for longer duration
varied among the five studies from 2 months to 5 years. And the
study of Tsibouris et al did not provide risk estimate for shorter
duration (o2 years). So, we defined longer duration as 1 year, 2
years, and 3 years, respectively, and carried out separate subgroup
meta-analysis. We did not find any significant difference for risk
reduction between longer duration and shorter duration, suggest-
ing that use of COX inhibitors might be independent of duration
response. In individual studies, Kastelein et al reported that
NSAIDs use for42 months was associated with a significant trend
towards a lower risk of neoplastic development than NSAIDs use
for 2 months or less, and Nguyen et al demonstrated that filled
COX inhibitors prescriptions for at least 12 months had a non-
significant greater reduction in EAC risk than those with o12
months’ prescriptions. Nevertheless, in another study of Nguyen
et al (2009), COX inhibitors use for43 years indicated a lower risk
reduction than COX inhibitors use for o3 years. And Vaughan
et al also showed lower protective effect of COX inhibitors use for
45 years compared with COX inhibitors use for o5 years. With
methodological limitations of meta-analysis and the varying
definitions for duration response in each included study, we were
not able to confirm the duration–response relationship for COX
inhibitors through meta-analysis. The optimal duration of COX
inhibitors use for chemoprevention in patients with BE needs to be
further explored.
Only three of the included studies offered risk estimates for dose
and frequency, making it difficult to draw conclusions of dose
effect and frequency effect. Tsibouris et al concluded that daily use
of non-aspirin COX inhibitors reduced cancer risk in patients with
BE. Vaughan et al stated that most of the COX inhibitor users took
one or more doses per day during regular use. But they found no
relation between frequency of NSAID use and risk of esophageal
cancer (o1 dose per day vs X1 dose per day). Kastelein et al
reported dose and frequency for nsNSAIDs (acetylsalicylic
acid4325mg per day, carbasalate calcium4325mg per day),
and low-dose aspirin (acetylsalicylic acidp100mg per day,
carbasalate calciump100mg per day). We could not confirm
which accurate dose was associated with protective effect through
meta-analysis. Corley et al suggested in their meta-analysis that
both intermittent and frequent medication use were protective,
with greater protection with more frequent use in the whole
population, which could help us understand this problem.
When stratified by medication type, there was also a negative
association between neoplastic progression and both low-dose
aspirin (37% reduction) and non-aspirin COX inhibitors (50%
reduction). Use of non-aspirin COX inhibitors seemed to be more
effective than use of low-dose aspirin. We were not able to provide
separate data for selective COX-2 inhibitors and nsNSAIDs as only
one study reported the information. Kastelein et al reported use of
selective COX-2 inhibitors and nsNSAIDs respectively, and
concluded that only use of nsNSAIDs significantly reduced risk
of EAC in patients with BE. As for individual type of COX
inhibitors, Tsibouris et al stated that only diclofenac daily
consumption yielded a protective effect. Additional studies are
necessary to determine which type of COX inhibitors is optimal.
Chemoprevention of other medications as PPIs and statins for
EAC in patients with BE has also been investigated for long, and
interest in combined use of COX inhibitors and these medications
has arisen recently. Among the included studies, only Kastelein
et al reported that use of both COX inhibitors and statins provided
a stronger risk reduction than use of COX inhibitors or statins
alone. We then carried out a subgroup meta-analysis to compare
the estimates of COX inhibitors use adjusting for other
medications to those that did not adjust. The results indicated a
non-significant greater risk reduction in neoplastic progression for
concomitant use of COX inhibitors and other medications
(PPIs/statins).
Although some previous epidemiological studies have con-
firmed the chemopreventive effect of COX inhibitors for EAC in
the whole population, the absence of BE states in cases and
controls might lead to a misunderstanding of how these
medications could exert their antitumour effect. Our meta-analysis
was the first to evaluate whether COX inhibitors can prevent
patients with BE from progressing into malignancy at great length.
Besides, we synthesised data on duration response and subgroups
for benefit (for example, by study design and medication type),
thus providing firmer summary estimates of the association.
Beales et al (2013) performed a meta-analysis of the relationship
between statins use and EAC development in BE patients. They
also investigated the association between COX inhibitors and the
risk of EAC in BE patients among five studies, and found that use
of COX inhibitors was associated with a significantly lower
incidence of EAC in BE patients (OR¼ 0.59, 95% CI: 0.45–0.77),
consistent with our results. However, they missed some original
studies in their meta-analysis, and they did not provide any
information on duration response or medication type.
Esophageal adenocarcinoma development experiences a long
procedure through a multi-step sequence of metaplasia-dysplasia-
adenocarcinoma. Cyclooxygenase inhibitors may act late or early
in the pathway. Understanding that COX inhibitors could prevent
BE from progressing into malignancy through our meta-analysis,
we were not sure whether these medications could lower the risk of
BE development in the first place. Anderson et al (2006) reported
that use of aspirin and NSAIDs was associated with a reduced risk
of BE (OR¼ 0.53, 0.31–0.90 and OR¼ 0.40, 0.19–0.81, respec-
tively). Omer et al (2012) also found that current aspirin users had
a lower risk for developing BE than non-users (OR¼ 0.56,
0.39–0.80). However, Thrift et al (2011) demonstrated that
aspirin use did not reduce the risk of BE (OR¼ 1.16, 0.71–1.43).
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Whether COX inhibitors may act at an early stage of EAC
development remains to be investigated.
Our study also had some limitations. First, all included studies
were observational ones, leading to lack of random allocation of
the intervention compared with RCTs. Bias due to unmeasured
confounding, for example, different medications use (PPIs and
statins), other health problems (angiocardiopathy) and complica-
tions, could distort the results. For instance, patients with
myocardial infarction use aspirin more often, and those with
complications such as reflux symptoms or upper gastrointestinal
ulcers might use COX inhibitors less frequently. Besides,
confounders included in adjusted estimates varied significantly
among these studies. Nevertheless, confounding was unlikely to
fully account for the protective association of COX inhibitors. Most
studies controlled for the most influential risk factors of EAC such
as age, sex, smoking, and alcohol use. Some of them further
adjusted for other suspected risk factors such as use of other
medications (PPIs and statins), or reflux symptoms, finding that
these further adjustments did not obviously change the effect
estimates. For instance, one study reported an age-, sex-, and pack-
years smoked-adjusted HR of 0.58 (95% CI 0.32–1.02), and found
the estimate to be significantly unchanged after further adjustment
for use of statins (HR 0.62 with 95% CI 0.34–1.10) (Kantor et al,
2012).
Second, we were not able to provide evidence for duration
response. Data on detailed dose and frequency were not available
in many studies, and duration for high intake of COX inhibitors
was obviously different in each study, making it difficult for us to
definitively draw conclusions of the accurate dose, frequency, or
duration of COX inhibitors needed for a greater antitumour effect.
Third, reverse causation might exist in the included studies. To
control for reverse causation in cohort studies, that is to avoid
prevalent or existing cases of cancer, those patients with BE who
were diagnosed as EAC during a given interval or had a follow-up
of less than that given interval, ranging from 5 months to 1 year
after the initial diagnosis of BE, were excluded from each
individual analysis. As for case–control studies, Tsibouris et al
stated that they removed patients who started COX inhibitors in
the 4 years before the diagnosis of EAC to avoid collecting data on
medication consumption caused by the underlying pathology,
thereby avoiding reverse causation. Thus, we were able to keep to a
minimum this possibility of reverse causation.
Fourth, we failed to address how to balance the risks and
benefits of COX inhibitors through meta-analysis. The well-
recognised side effects of aspirin and NSAIDs were upper
gastrointestinal bleeding, peptic ulceration, and haemorrhagic
stroke. Many approaches to reduce harmful effects of these
medications were under investigation, including co-administration
with PPIs, histamine-2 receptor antagonists, and Helicobacter
pylori eradiation.
Additional well-designed epidemiological studies are needed to
enhance our understanding of the relationship between COX
inhibitors use and neoplastic development in patients with BE,
especially high-quality double-blinded RCTs. Heath et al (2007)
has published results of an RCT on behalf of the Chemoprevention
for Barrett’s Esophagus Trial (CBET) Research Group. The reason
why we did not bring it in our meta-analysis was that the outcomes
did not meet with our inclusion criteria. Disappointingly, results of
the phase II b multicentre trial indicated lack of secondary
chemoprevention of celecoxib in patients with Barrett’s dysplasia,
which contradicted our own data. The outcomes of the RCT
measured change from baseline to the active treatment period (48
weeks) in the following parameters: the proportion of biopsy
samples exhibiting dysplasia, the highest grade of dysplasia, the
extent of HGD/low-grade dysplasia (LGD), and the surface area
affected by BE. However, our meta-analysis measured the risk of
neoplastic progression in patients with BE, which was totally
different from the RCT. Moreover, the treatment duration was set
as 48 weeks to at most 2 years in the RCT, which presumably is too
short to reliably investigate the occurrence of EAC in most of the
patients. And the number of patients (82) with BE included in the
trial was rather small. All these contributed to the contradiction
between our analysis and the RCT. However, the UK ASPECT trial
utilising aspirin is in follow-up and should provide much more
data soon.
In summary, our meta-analysis shows a negative association
between COX inhibitors use and the risk of neoplastic progression
in patients with BE. Both non-aspirin COX inhibitors and low-
dose aspirin are associated with a reduced risk of neoplasia, and
non-aspirin COX inhibitors seem to be more effective. However,
COX inhibitors use seems to be independent of duration response.
Future research should include more well-designed RCTs on the
relationship between COX inhibitors use and the risk of EAC
development in patients with BE.
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APPENDIX A
APPENDIX A MEDLINE search strategy
Key words and medical subject heading (Mesh) terms for the
MEDLINE search included: (‘Barrett Esophagus’ [Mesh]) AND
(‘Anti-Inflammatory Agents, Non-Steroidal’ [Mesh] OR ‘non-
steroidal anti-inflammatory drugs’ OR diclofenac OR indometha-
cin OR aspirin OR ibuprofen OR naproxen OR ketorolac OR
etodolac OR sulindac OR ‘COX2-inhibitors’ OR celecoxib OR
rofecoxib OR valdecoxib).
APPENDIX B
APPENDIX B Description of quality score
The 9-star Newcastle-Ottawa Scale (NOS) evaluates the study
quality in three categories: selection, comparability, and exposure
(case–control studies) or outcome (cohort studies). The NOS
assigns a maximum of four questions for selection of study groups,
two questions for comparability of study groups, and three
questions for ascertainment of the outcome of interest. All
questions have a score of 1, except for comparability, for which
separate points are awarded for controlling for age and/or sex
(maximum, 2 points). Nine points on the NOS reflect the highest
study quality. Any discrepancies were resolved by a joint re-
evaluation of the original articles.
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